» Articles » PMID: 29348737

PET Imaging of Adenosine 2A Receptors in Neuroinflammatory and Neurodegenerative Disease

Overview
Specialty Radiology
Date 2018 Jan 20
PMID 29348737
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Adenosine receptors are G-protein coupled P1 purinergic receptors that are broadly expressed in the peripheral immune system, vasculature, and the central nervous system (CNS). Within the immune system, adenosine 2A (A) receptor-mediated signaling exerts a suppressive effect on ongoing inflammation. In healthy CNS, A receptors are expressed mainly within the neurons of the basal ganglia. Alterations in A receptor function and expression have been noted in movement disorders, and in Parkinson's disease pharmacological A receptor antagonism leads to diminished motor symptoms. Although A receptors are expressed only at a low level in the healthy CNS outside striatum, pathological challenge or inflammation has been shown to lead to upregulation of A receptors in extrastriatal CNS tissue, and this has been successfully quantitated using positron emission tomography (PET) imaging and A receptor-binding radioligands. Several radioligands for PET imaging of A receptors have been developed in recent years, and A receptor-targeting PET imaging may thus provide a potential additional tool to evaluate various aspects of neuroinflammation . This review article provides a brief overview of A receptors in healthy brain and in a selection of most important neurological diseases and describes the recent advances in A receptor-targeting PET imaging studies.

Citing Articles

Brain Specific RagA Overexpression Triggers Depressive-Like Behaviors in Mice via Activating ADORA2A Signaling Pathway.

Zhao J, Sun Y, Feng Y, Rong J Adv Sci (Weinh). 2024; 11(45):e2404188.

PMID: 39373701 PMC: 11615787. DOI: 10.1002/advs.202404188.


Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development.

Majumdar M, Badwaik H Curr Drug Targets. 2024; 25(15):987-1011.

PMID: 39313872 DOI: 10.2174/0113894501312703240826070530.


Radiosynthesis and In Vitro Evaluation of [C]tozadenant as Adenosine A Receptor Radioligand.

Humpert S, Schneider D, Lang M, Schulze A, Neumaier F, Holschbach M Molecules. 2024; 29(5).

PMID: 38474602 PMC: 10935082. DOI: 10.3390/molecules29051089.


Neuroinflammation and Mitochondrial Dysfunction in Parkinson's Disease: Connecting Neuroimaging with Pathophysiology.

Pizarro-Galleguillos B, Kunert L, Bruggemann N, Prasuhn J Antioxidants (Basel). 2023; 12(7).

PMID: 37507950 PMC: 10375976. DOI: 10.3390/antiox12071411.


Bidirectional Control between Cholesterol Shuttle and Purine Signal at the Central Nervous System.

Passarella D, Ronci M, Di Liberto V, Zuccarini M, Mudo G, Porcile C Int J Mol Sci. 2022; 23(15).

PMID: 35955821 PMC: 9369131. DOI: 10.3390/ijms23158683.


References
1.
Frischer J, Bramow S, Dal-Bianco A, Lucchinetti C, Rauschka H, Schmidbauer M . The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009; 132(Pt 5):1175-89. PMC: 2677799. DOI: 10.1093/brain/awp070. View

2.
Phillis J . The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res. 1995; 705(1-2):79-84. DOI: 10.1016/0006-8993(95)01153-6. View

3.
Orr A, Hsiao E, Wang M, Ho K, Kim D, Wang X . Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. Nat Neurosci. 2015; 18(3):423-34. PMC: 4340760. DOI: 10.1038/nn.3930. View

4.
Mankoff D . A definition of molecular imaging. J Nucl Med. 2007; 48(6):18N, 21N. View

5.
Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg S . Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem. 2003; 278(47):46741-9. DOI: 10.1074/jbc.M306451200. View